Top

Published in:

01-08-2011 | Original Article

Association between timing of zoledronic acid infusion and hip fracture healing

Authors: C. Colón-Emeric, L. Nordsletten, S. Olson, N. Major, S. Boonen, P. Haentjens, P. Mesenbrink, J. Magaziner, J. Adachi, K. W. Lyles, L. Hyldstrup, C. Bucci-Rechtweg, C. Recknor, for the HORIZON Recurrent Fracture Trial

Published in: Osteoporosis International | Issue 8/2011

Abstract

Summary

Patients in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Recurrent Fracture Trial were assessed for evidence of delayed hip fracture healing. No association was observed between zoledronic acid (ZOL) and delayed healing. We conclude that ZOL has no clinically evident effect on fracture healing, even when the drug is infused in the immediate postoperative period.

Introduction

Intravenous zoledronic acid 5 mg (ZOL) given after a hip fracture reduces secondary fracture rates and mortality. It has been postulated that bisphosphonates may affect healing if given soon after a fracture. We sought to determine whether the timing of ZOL infusion affected the risk of delayed hip fracture healing.

Methods

In the HORIZON Recurrent Fracture Trial, patients were randomized within 90 days of a low-trauma hip fracture to receive either once-yearly ZOL (n = 1,065) or placebo (n = 1,062). Clinical symptoms of delayed hip fracture healing were sought at randomization, 6 months and 12 months after fracture; if present, a central adjudication committee blinded to treatment assignment reviewed radiographs and clinical records. Median follow-up was 1.9 years.

Results

The overall incidence of delayed healing was 3.2% (ZOL) and 2.7% (placebo; odds ratio [OR], 1.17; 95% confidence interval [CI], 0.72–1.90; p = 0.61). Logistic regression models revealed no association between ZOL and delayed healing even after adjusting for other risk factors (OR, 1.21; 95% CI, 0.74–1.99; p = 0.44). There was no interaction by timing of infusion, and nonunion rates were similar even when ZOL was given within 2 weeks of hip fracture repair. NSAID use was significantly associated with delayed fracture healing (OR, 2.55; 95% CI, 1.49–4.39; p < 0.001).

Conclusions

ZOL has no clinically evident effect on fracture healing, even when the drug is infused in the immediate postoperative period.

Magaziner J, Lydick E, Hawkes W, Fox KM, Zimmerman SI, Epstein RS, Hebel JR (1997) Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health 87:1630–1636PubMedCrossRef

Melton LJ III (2003) Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 18:1139–1141PubMedCrossRef

Colón-Emeric C, Kuchibhatla M, Pieper C, Hawkes W, Fredman L, Magaziner J, Zimmerman S, Lyles KW (2003) The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int 14:879–883PubMedCrossRef

Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef

Fleisch H (2001) Can bisphosphonates be given to patients with fractures? J Bone Miner Res 16:437–440PubMedCrossRef

Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301PubMedCrossRef

Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17:2237–2246PubMedCrossRef

Goodship AE, Walker PC, McNally D, Chambers T, Green JR (1994) Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 5(Suppl 7):S53–S55PubMed

Marsh D (1998) Concepts of fracture union, delayed union, and nonunion. Clin Orthop Relat Res 355:S22–S30PubMedCrossRef

10.

Sama AA, Khan SN, Myers ER, Huang RC, Cammisa FP Jr, Sandhu HS, Lane JM (2004) High-dose alendronate uncouples osteoclast and osteoblast function: a study in a rat spine pseudarthrosis model. Clin Orthop Relat Res 425:135–142PubMedCrossRef

11.

Amanat N, McDonald M, Godfrey C, Bilston L, Little D (2007) Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 22:867–876PubMedCrossRef

12.

Li J, Mori S, Kaji Y, Kawanishi J, Akiyama T, Norimatsu H (2000) Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J Bone Miner Res 15:2042–2051PubMedCrossRef

13.

Frihagen F, Nordsletten L, Madsen JE (2007) Hemiarthroplasty or internal fixation for intracapsular displaced femoral neck fractures: randomised controlled trial. BMJ 335:1251–1254PubMedCrossRef

14.

Rodriguez-Merchan EC, Forriol F (2004) Nonunion: general principles and experimental data. Clin Orthop Relat Res 419:4–12PubMedCrossRef

15.

Eriksen EF, Lyles KW, Colón-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P (2009) Antifracture efficacy and reduction of mortality in relation to timing of first dose of zoledronic acid after hip fracture. J Bone Miner Res 24:1308–1313PubMedCrossRef

16.

Lynch JR, Taitsman LA, Barei DP, Nork SE (2008) Femoral nonunion: risk factors and treatment options. J Am Acad Orthop Surg 16:88–97PubMed

17.

Boyce RW, Paddock CL, Gleason JR, Sletsema WK, Eriksen EF (1995) The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 10:211–221PubMedCrossRef

18.

Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H (2001) Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res 16:429–436PubMedCrossRef

19.

Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimatsu H (1999) Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res 14:969–979PubMedCrossRef

20.

Amanat N, Brown R, Bilston LE, Little DG (2005) A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res 23:1029–1034PubMedCrossRef

21.

Koivukangas A, Tuukkanen J, Kippo K, Jamsa T, Hannuniemi R, Pasanen I, Vaananen K, Jalovaara P (2003) Long-term administration of clodronate does not prevent fracture healing in rats. Clin Orthop Relat Res 408:268–278PubMedCrossRef

22.

Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Rodan GA (1996) Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14:74–79PubMedCrossRef

23.

Adolphson P, Abbaszadegan H, Boden H, Salemyr M, Henriques T (2000) Clodronate increases mineralization of callus after Colles' fracture: a randomized, double-blind, placebo-controlled, prospective trial in 32 patients. Acta Orthop Scand 71:195–200PubMedCrossRef

24.

Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH (2004) Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 19:1779–1786PubMedCrossRef

25.

Solomon DH, Hochberg MC, Mogun H, Schneeweiss S (2009) The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Osteoporos Int 20:895–901PubMedCrossRef

26.

Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349–353PubMedCrossRef

27.

Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224–231PubMedCrossRef

28.

Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304–1306PubMedCrossRef

29.

Bhandari M, Guyatt GH, Swiontkowski MF, Tornetta P III, Sprague S, Schemitsch EH (2002) A lack of consensus in the assessment of fracture healing among orthopaedic surgeons. J Orthop Trauma 16:562–566PubMedCrossRef

30.

Einhorn TA (1998) Breakout session. 1: definitions of fracture repair. Clin Orthop Relat Res 355:S353PubMedCrossRef

31.

Hammer R, Hammerby S, Lindholm B (1985) Accuracy of radiologic assessment of tibial shaft fracture union in humans. Clin Orthop 199:233–238PubMed

Title: Association between timing of zoledronic acid infusion and hip fracture healing
Authors: C. Colón-Emeric
L. Nordsletten
S. Olson
N. Major
S. Boonen
P. Haentjens
P. Mesenbrink
J. Magaziner
J. Adachi
K. W. Lyles
L. Hyldstrup
C. Bucci-Rechtweg
C. Recknor
for the HORIZON Recurrent Fracture Trial
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 8/2011
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-010-1473-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Association between timing of zoledronic acid infusion and hip fracture healing

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2011

Bone status in a mouse model of genetic hemochromatosis

Quantitative genetic study of the circulating osteopontin in community-selected families

Prevalence of vertebral fractures on chest radiographs of elderly African American and Caucasian women

A review of patient-centred post-fracture interventions in the context of theories of health behaviour change

A team approach: implementing a model of care for preventing osteoporosis related fractures

Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1–34) for 18 months contribute to improvement of bone strength in ovariectomized monkeys